Gobind Singh
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,735
Out of 4,735 analysts
9
Total ratings
6.67%
Success rate
-56.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gobind Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Assumes: Buy | $35 | $16.88 | +107.35% | 1 | Sep 19, 2022 | |
| ELEV Elevation Oncology | Assumes: Buy | $7.5 | $0.71 | +953.96% | 1 | Sep 19, 2022 | |
| IMUX Immunic | Assumes: Buy | $26 | $0.95 | +2,636.84% | 2 | Sep 19, 2022 | |
| PRTA Prothena Corporation | Initiates: Market Outperform | $77 | $14.11 | +445.71% | 1 | Nov 19, 2021 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $60 → $70 | $38.10 | +83.73% | 4 | Nov 15, 2021 |
AnaptysBio
Sep 19, 2022
Assumes: Buy
Price Target: $35
Current: $16.88
Upside: +107.35%
Elevation Oncology
Sep 19, 2022
Assumes: Buy
Price Target: $7.5
Current: $0.71
Upside: +953.96%
Immunic
Sep 19, 2022
Assumes: Buy
Price Target: $26
Current: $0.95
Upside: +2,636.84%
Prothena Corporation
Nov 19, 2021
Initiates: Market Outperform
Price Target: $77
Current: $14.11
Upside: +445.71%
Protagonist Therapeutics
Nov 15, 2021
Maintains: Market Outperform
Price Target: $60 → $70
Current: $38.10
Upside: +83.73%